Metformin modifies plasma microbial-derived extracellular vesicles in polycystic ovary syndrome with insulin resistance
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Hu L, Hong G, Li J, Chen M, Chang CJ, Cheng PJ, Zhang Z, Zhang X, Chen H, Zhuang Y, Li Y
Journal
Journal of ovarian research
Year
2024
Keywords:
EVs, Full-length 16S rRNA, Metformin, Microbial community, PCOS, PCOS-IR
INTRODUCTION: This study investigated changes in plasma microbial-derived extracellular vesicles (EVs) in patients with polycystic ovary syndrome and insulin resistance (PCOS-IR) before and after metformin treatment, and aimed to identify bacterial taxa within EVs that were biologically and statistically significant for diagnosis and treatment. METHODS: The case-control study was conducted at Xiamen Chang Gung Hospital, Hua Qiao University. Plasma samples were collected from five PCOS-IR patients of childbearing age before and after 3 months of metformin treatment, and the samples were sequenced. The diversity and taxonomic composition of different microbial communities were analyzed through full-length 16 S glycosomal RNA gene sequencing. RESULTS: After metformin treatment, fasting plasma glucose levels and IR degree of PCOS-IR patients were significantly improved. The 16 S analysis of plasma EVs from metformin-treated patients showed higher microbial diversity. There were significant differences in EVs derived from some environmental bacteria before and after metformin treatment. Notably, Streptococcus salivarius was more abundant in the metformin-treated group, suggesting it may be a potential probiotic. DISCUSSION: The study demonstrated changes in the microbial composition of plasma EVs before and after metformin treatment. The findings may offer new insights into the pathogenesis of PCOS-IR and provide new avenues for research.
Experiment 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Blood plasma Blood plasm,Plasma,Portion of blood plasma,Portion of plasma,Blood plasma,blood plasma
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Polycystic ovary syndrome Cystic disease of ovaries,hyperandrogenemia,Multicystic ovaries,multicystic ovaries,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovarian Syndromes, Polycystic,Ovaries, Sclerocystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,PCO - Polycystic ovaries,Pco1,PCOD - Polycystic ovarian disease,PCOS,Pcos,PCOS - Polycystic ovarian syndrome,PCOS1,Polycystic ovarian disease,polycystic ovarian disease,Polycystic ovarian syndrome,Polycystic ovaries,polycystic ovaries,Polycystic ovaries (disorder),polycystic ovary,polycystic ovary syndrome,polycystic ovary syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary,Sclerocystic Ovary Syndrome,Stein Leventhal Syndrome,Stein-Leventhal synd.,Stein-Leventhal Syndrome,Stein-Leventhal syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal,Polycystic ovary syndrome
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- EBF (EVs extracted from patients before treatment) group
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- EAF (EVs extracted from patients after treatment) group
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Polycystic ovary syndrome- Insulin-resistant patients of childbearing age, whose plasma EVs(extracellular vesicles) were extracted after 3 months of metformin treatment.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 5
- Group 1 sample size Number of subjects in the case (exposed) group
- 5
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- 6 months
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V1-V9
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Sequencing platform: "PacBio RS" is not in the list (DNA-DNA Hybridization, Human Intestinal Tract Chip, Illumina, Ion Torrent, Non-quantitative PCR, PhyloChip, Roche454, RT-qPCR, Mass spectrometry, Nanopore, ...) of allowed values.PacBio RS
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Alpha Diversity
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- decreased
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 6B
Description: Analysis of microbial species diversity. Microbial cladogram (LEfSe).
Abundance in Group 1: increased abundance in EAF (EVs extracted from patients after treatment) group
| NCBI | Quality Control | Links |
|---|---|---|
| Mesorhizobium | ||
| unclassified Mesorhizobium |
Revision editor(s): ShadeAkinremi, Victoria
Signature 2
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 6B
Description: Analysis of microbial species diversity. Microbial cladogram (LEfSe).
Abundance in Group 1: decreased abundance in EAF (EVs extracted from patients after treatment) group
| NCBI | Quality Control | Links |
|---|---|---|
| Sphingobacterium hotanense |
Revision editor(s): ShadeAkinremi, Victoria
Experiment 2
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Differences from previous experiment shown
Subjects
Lab analysis
Statistical Analysis
- Statistical test
- Mann-Whitney (Wilcoxon)
Alpha Diversity
- Simpson Estimator of species richness and species evenness: more weight on species evenness
- decreased
Signature 1
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 6C
Description: Analysis of microbial species diversity. Microbial cladogram (Wilcoxon rank-sum test).
Abundance in Group 1: increased abundance in EAF (EVs extracted from patients after treatment) group
| NCBI | Quality Control | Links |
|---|---|---|
| unclassified Mesorhizobium |
Revision editor(s): Victoria
Signature 2
Reviewed Marked as Reviewed by KateRasheed on 2025-6-11
Source: Figure 6C
Description: Analysis of microbial species diversity. Microbial cladogram (Wilcoxon rank-sum test).
Abundance in Group 1: decreased abundance in EAF (EVs extracted from patients after treatment) group
| NCBI | Quality Control | Links |
|---|---|---|
| Sphingobacterium hotanense |
Revision editor(s): Victoria
Retrieved from "https://bugsigdb.org/w/index.php?title=38956672&oldid=205491"
